Heparanase-Neutralizing A54 Monoclonal Antibody
Hadasit Medical Research Services and Development Ltd.
A patent family: one line of work, grouped by real continuity rather than by a technology label
inferred from titles. 2 of these applications claim priority to application PCT/IL2021/050830, filed Jul 6, 2021. A shared origin can cover several different claimed inventions, which is why members here may not share a title. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Holder | Status | Expires | Patent lifetimeUsedRemaining | Confidence |
|---|---|---|---|---|---|---|
| US 12,503,518 | Heparanase-Neutralizing A54 Monoclonal Antibody Technion Research & Development Foundation Limited and Hadasit Medical Research Services and Development Ltd. In force · High confidence UsedRemaining | Technion Research & Development Foundation Limited and Hadasit Medical Research Services and Development Ltd. | In force | High confidence | ||
| US 12,606,637 | Heparanase-Neutralizing A54 Monoclonal Antibody In force · High confidence | Hadasit Medical Research Services and Development Ltd. | In force | High confidence |
2 of 2 records shown. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
Updated Nov 22, 2026 · includes USPTO assignment data published Nov 21, 2026, status data published Nov 22, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.